Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection? DOI Open Access
Yue Hu, Zheng Li,

Weilan He

et al.

Hepatology, Journal Year: 2023, Volume and Issue: 78(4), P. E76 - E77

Published: July 17, 2023

1Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women's Children's Central Hospital, School Medicine, University Electronic Science Technology China, Chengdu, China 2Division Thoracic Tumor Multimodality Treatment Department Radiation Oncology, Cancer Center, West Sichuan University, Data availability statement: The data that support the findings this study are all included in article. Yue Hu Zheng Li: Contributed equally as co-first authors. Correspondence Xinran Cheng, Riyue Road 1617#, Qingyang District, 610073, China. Email: [email protected]

Language: Английский

SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease DOI Creative Commons
Hendrik Luxenburger, Robert Thimme

Gut, Journal Year: 2023, Volume and Issue: 72(9), P. 1783 - 1794

Published: June 14, 2023

SARS-CoV-2 infection may affect the liver in healthy individuals but also influences course of COVID-19 patients with chronic disease (CLD). As described individuals, a strong SARS-CoV-2-specific adaptive immune response is important for outcome COVID-19, however, knowledge on CLD limited.Here, we review clinical and immunological features CLD. Acute injury occurs many cases be induced by multiple factors, such as cytokines, direct viral or toxic effects drugs. In CLD, have more severe promote decompensation particularly cirrhosis. Compared responses impaired after both, natural vaccination improves at least partially booster vaccination.Following vaccination, rare acute vaccine-induced development autoimmune-like hepatitis been reported. However, concomitant elevation enzymes reversible under steroid treatment.

Language: Английский

Citations

16
Distinct immune memory induced by SARS-CoV-2 in convalescent liver transplant recipients DOI Creative Commons

Mengcheng Liu,

Feng Wu,

Binwei Duan

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 2, 2025

The understanding of how the host immune response differs in T-cell phenotype and memory formation during SARS-CoV-2 infection liver transplant recipients (LTRs) remains limited. LTRs who recovered from COVID-19 without prior vaccination represent a unique population for studying responses to SARS-CoV-2. Six with positive neutralizing antibodies (nAb+) six negative nAb (nAb-) were included at 6 months following infection. It was found that nAb+ had higher anti-RBD IgG titers greater percent inhibition compared nAb- LTRs. Fifteen subsets identified convalescent LTRs, it shown only terminal effector CD8+ - 3 decreased group, while elevated IL-10 expression levels group. After stimulation XBB spike peptide pool vitro, observed group exhibited an increase CD4+ cells lower PD-1 expression, reduction 2 cells, showed high CTLA-4 cells. Four SARS-CoV-2-specific identified, TNF-α IFN-γ 1 both groups. Perforin mainly detected In addition these proportional differences, stem cell IL-17A also These findings suggest developed exhibit stronger responses, more robust activation recall, This study underscores importance recovery guiding strategies managing immunity

Language: Английский

Citations

0
Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review DOI Creative Commons

Konstantina Toutoudaki,

Melitini Dimakakou,

Θεόδωρος Ανδρουτσάκος

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 452 - 452

Published: Feb. 16, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing disease 2019 (COVID-19), has led to a pandemic with more than 6.5 million deaths worldwide. Patients liver cirrhosis (PWLC) are regarded as prone severe COVID-19. Vaccination against SARS-CoV-2 been proven be the most effective measure COVID-19 and variety of different vaccines have approved for use; namely mRNA vector-based, inactivated, whole virion, protein subunit vaccines. Unfortunately, only small number PWLC were included in phase I–III vaccine trials, raising concerns regarding their efficacy safety this population. The authors, review, present available data anti-SARS-CoV-2 vaccination discuss post-vaccination antibody responses. Overall, all seem extremely safe, few insignificant adverse events, efficient, leading lower rates hospitalization COVID-19-related mortality. T- B-cell responses, on other hand, remain an enigma, especially patients decompensated disease, since these show titers antibodies some studies, rapid waning. However, finding is not consistent, its clinical impact still undetermined.

Language: Английский

Citations

5
Liver Transplantation: Protocol for Recipient Selection, Evaluation, and Assessment DOI Open Access
Ifrah Fatima, Vinay Jahagirdar, Anand V. Kulkarni

et al.

Journal of Clinical and Experimental Hepatology, Journal Year: 2023, Volume and Issue: 13(5), P. 841 - 853

Published: April 17, 2023

Language: Английский

Citations

4
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis DOI Creative Commons

Lichen Ouyang,

Gang Lei,

Yeli Gong

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 11, 2024

The immunogenicity of COVID-19 vaccines in patients with liver cirrhosis remains largely unknown. purpose this meta-analysis was to investigate the and compare humoral cellular immune responses following complete vaccination between healthy controls. A systematic literature search conducted PubMed, EMBASE, Web Science from 1 January 2020 22 August 2023. Sixteen studies 2127 were included. pooled seroconversion rate 92.4% (95% CI, 86.2%–96%, I2 = 90%) significant between-study heterogeneity. Moreover, elicited a higher response compensated as compared decompensated (RR 1.069, 95% 1.011–1.131, 17%, p .019). Additionally, 10 included for comparison analysis results showed that slightly lower controls 0.972, 0.955–0.989, 66%, .001). Meanwhile, RR vs. 0.678 0.563–0.817, 0, < .0001). Our demonstrated diminished cirrhosis. Patients particularly who have completed full-doses should receive continuous attention preemptive measures.

Language: Английский

Citations

1
Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study DOI Creative Commons
Pimsiri Sripongpun, Nawamin Pinpathomrat,

Ratchanon Sophonmanee

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(9), P. 1455 - 1455

Published: Sept. 4, 2023

This study aimed to evaluate the antibody and cellular responses different coronavirus 2019 (COVID-19) vaccination regimens in patients with cirrhosis assess response after a vaccine booster. We conducted prospective observational of 89 41 healthy volunteers who received two COVID-19 doses. Next, we prospectively evaluated 24 booster dose. In both studies, blood samples were collected before 4 weeks vaccination, anti-spike receptor-binding domain protein IgG levels, T-cell phenotypes, effector functions assessed. The heterologous regimen (CoronaVac [SV]/AstraZeneca [AZ]) produced better CD4+IFNg+ T cell compared homogeneous regimens. second dose was similar volunteers. Patients mRNA had significantly increased titers those AZ vaccine. cirrhosis, SV/AZ resulted immune than AZ/AZ SV/SV Moreover, led greater increase

Language: Английский

Citations

3
The impact of COVID-19 on liver transplantation: challenges and perspectives DOI Creative Commons
Ifrah Fatima, Nikki Duong

Therapeutic Advances in Gastroenterology, Journal Year: 2023, Volume and Issue: 16

Published: Jan. 1, 2023

The coronavirus disease 2019 (COVID-19) pandemic presented unique challenges to patients with decompensated cirrhosis awaiting transplant, respect accessing medical facilities for routine clinic visits, imaging, laboratory workup, or endoscopies. There was a delay in organ procurement that led decrease the number of liver transplants (LTs) and an increase morality waitlisted at beginning pandemic. LT numbers later equalized pre-pandemic due combined efforts adaptability transplant centers as well dynamic guidelines. Due being immunosuppressed, demographics were increased risk infection. Although there is higher rate mortality morbidity chronic disease, itself not factor COVID-19. no difference overall compared non-LT patients, factors same: age, hypertension, diabetes, obesity, kidney disease. most common causes death respiratory complications. Liver-related deaths reported 1.6% patients. optimal timing transplantation post-infection depends on various factors, such severity injury, presence comorbidities, progression underlying enough data available COVID-19 cholangiopathy cases will be seen future require LT. are some concerns lower immunogenicity vaccines but evidence suggests safe well-tolerated.

Language: Английский

Citations

2
Measures to Increase Immunogenicity of SARS-CoV-2 Vaccines in Solid Organ Transplant Recipients: A Narrative Review DOI Creative Commons
Bo Yu, Christina Tamargo, Daniel C. Brennan

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(12), P. 1755 - 1755

Published: Nov. 25, 2023

Purpose of review: To review the data on immunogenicity COVID-19 vaccines, administered by different strategies, in solid organ transplant recipients (SOTRs). Recent findings: booster vaccines were given to SOTRs as a widespread practice many centers, mostly third and/or fourth dose an extended vaccine series, with significantly improved humoral response compared initial two-dose scheme. However, one-third remained unresponsive, despite these boosters. Next steps: Vaccination standard dosing remains most feasible strategy for attaining protection against COVID-19. Additional doses and temporarily holding or reducing mycophenolate mofetil/mycophenolic acid may provide according recent studies demonstrating some efficacy measures. Preexposure prophylaxis monoclonal antibodies showed benefit immunocompromised patients but is no longer recommended National Institutes Health (NIH) due diminished Omicron variants. Screening presence titers SARS-CoV-2-specific not clinical settings. T cell-based techniques are needed evaluate risk infection. As SARS-CoV-2 continues evolve, new based conservative protein component/complexes COVID virus, addition its spike protein, warranted offer prolonged protection.

Language: Английский

Citations

2
COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses DOI Creative Commons

Inês Canha,

Mário Jorge Silva,

Maria Azevedo Silva

et al.

GE Portuguese Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 31(5), P. 325 - 337

Published: Nov. 15, 2023

Three years after the beginning of SARS-CoV-2 pandemic, safety and efficacy COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study safety, immunological, clinical responses LC vaccination.

Language: Английский

Citations

1
Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis DOI Creative Commons
Guanglin Xiao, Taiyu He,

Biqiong Zhang

et al.

International Journal of Public Health, Journal Year: 2024, Volume and Issue: 69

Published: Nov. 21, 2024

This review aimed to assess the safety and efficacy of SARS-CoV-2 vaccines in patients with chronic liver disease (CLD).

Language: Английский

Citations

0